PR86484

LONDON, Nov. 9, 2020, /PRNewswire=KYODO JBN/--

A large, landmark study published in the American Cancer Society's prestigious

journal 'Cancer Cytopathology' shows that a simple non-invasive blood test

(liquid biopsy) can accurately differentiate between non-cancerous tumors

versus cancerous growths.

These findings were based on a multi-institutional, international

collaborative study sponsored by Datar Cancer Genetics where the investigators

evaluated blood samples from more than 30,000 participants, which included

~9,000 known cases and ~6,000 suspected cases of cancers, 700 individuals with

non-cancerous tumors and 14,000 healthy individuals. The study encompassed 27

types of solid organ cancers including brain tumors.

The investigators evaluated the presence of circulating, tiny clusters of

tumors, highly prevalent in the blood of cancer patients and undetectable in

individuals without cancer. The investigators could also establish precise

organ affected by the tumor with more than 90% accuracy.

Significantly, the test will greatly help individuals reporting with suspicious

growths in various organs such as breast, lung, prostate, colon, brain.  It is

noteworthy that a large proportion of individuals who undergo biopsy on

suspicion of malignancy are detected with benign tumors who could be spared

risky invasive and resource intensive biopsies. Also, the blood test can help

in the diagnosis of cases where invasive biopsies are unviable due to various

reasons such as location of the tumor close to a vital organ or blood vessel or

reluctance of patients besides co-morbidities.

The technology and the test are developed by Datar Cancer Genetics. The test is

expected to be commercially available shortly. These findings are bound to have

a profound impact on cancer diagnosis.

Commenting upon the results, Dr Nicholas Plowman, MD, Medical Oncologist at

Department of Clinical Oncology, St Bartholomew's Hospital, London, United

Kingdom, and one of the authors of the paper said that 'This study is the

largest of its kind and shows the meaningful potential of liquid biopsies,

which so far have been grossly under-rated, at least partly as the previous

capture methods were inferior. Harvesting tumor clusters from peripheral blood

is akin to a non-invasive micro-biopsy of the tumor. Evaluation of these

clusters can facilitate diagnostic triaging as well as guidance in suspected

cancer cases. The test is not only patient friendly, but it can also significantly

reduce the burden on the already overburdened cancer diagnosis infrastructure.'

The research is published online

(https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22366 ).  

About Datar Cancer Genetics

Datar Cancer Genetics is a leading cancer research corporation specialising in

non-invasive techniques for better diagnosis, treatment decisions, and

management of cancer. The Company's state-of-the-art cancer research centre is

NABL, ISO, CAP and CLIA accredited.

Access Publication of the study at

https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22366 

https://datarpgx.com/publications/ 

Website

datarpgx.com 

Logo - https://mma.prnewswire.com/media/1086492/Datar_Cancer_Genetics_Logo.jpg 

CONTACT: Dr Vineet Datta

         drvineetdatta@datarpgx.com

SOURCE:  Datar Cancer Genetics